12th Annual North Carolina Research Triangle Pulmonary Hypertension Symposium

Duke University and University of North Carolina’s 12th Annual North Carolina Research Triangle Pulmonary Hypertension Symposium partnered with PHA through the Building Medical Education in PH program.

Date and time

Friday, November 13, 2020
12 p.m. to 4:30 p.m.

Format

Zoom Webinar

Download the Agenda Register Here

Course Overview

The field of pulmonary arterial hypertension is a rapidly developing one, with multiple new treatments introduced in the last 25 years. This has created a steep learning curve for pulmonologists and cardiologists treating this disease, as well as primary care physicians who must remain mindful to consider the diagnosis in their patients. We seek to enhance the knowledge base of these physicians keeping them up to date on the evolving body of knowledge on pulmonary vascular disease. This dynamic state of the field serves to perpetuate a gap in regard to the knowledge of appropriate diagnostic procedures, proper treatment choices, and timing in advancement of care to pulmonary hypertension specialty centers. It is imperative that those treating this specialized disease have a thoroughly grounded knowledge of the appropriate work up, treatment, and care of the pulmonary arterial hypertension (PAH) patient.

The ACCP, AHA, ERS/ESC and WHO have convened on multiple occasions to develop consensus guidelines for the diagnosis and treatment of PAH. These guidelines have been published in prominent medical journals and presented at national meetings, thus exposing thousands of practitioners to these standardized approaches and promoting appropriate, structured care paradigms. The 12th Annual Research Triangle PH symposium will reinforce the current diagnostic and management guidelines of PAH put forth by the 6th World Symposium on Pulmonary Hypertension in 2018, as well as updates from subsequent national and international conferences. In addition, there will be a focus on the different subgroups of Pulmonary Hypertension, covering the diagnosis, management, and treatment for patients with WHO group 2-5 PH. Information about clinical trials, precision medicine, and challenging and nuanced presentations of PH will also be provided. It will provide a plentiful forum for questions and discussion, providing reinforcement of appropriate care practices and availability of regional referral centers.

Course Directors

H. James Ford, MD
Associate Professor of Medicine
Director, Pulmonary Hypertension Program
Division of Pulmonary and Critical Care Medicine
University of North Carolina at Chapel Hill

Terry Fortin, MD
Associate Professor of Medicine
Co-Director, Pulmonary Vascular Disease Center
Division of Cardiology
Duke University Medical Center 

Invited Faculty

Mazen Al-Qadi, MD
Assistant Professor of Medicine
Pulmonary Hypertension Program
Division of Pulmonary and Critical Care Medicine
University of North Carolina at Chapel Hill

Danielle Burkett, CMA
Duke Pulmonary Vascular Disease Center
Duke University Medical Center

Traci Housten, RN, MS
Program Manager
Johns Hopkins Pulmonary Hypertension Program
Johns Hopkins Hospital

Richard Krasuski, MD
Professor of Medicine
Division of Cardiology
Duke University Medical Center

Irene Lang, MD
Director, Pulmonary Vascular Disease Clinic
Professor of Vascular Biology
Department of Cardiology
AKH-Vienna, Medical University of Vienna
Austria

Barbara LeVarge, MD
Assistant Professor of Medicine
Associate Director, Pulmonary Hypertension Program
University of North Carolina at Chapel Hill 

Stephen Mathai, MD, MHS
Associate Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Johns Hopkins University School of Medicine

Steven Nathan, MD
Medical Director
Advanced Lung Disease, Lung Transplant & Inova Lung Services
Inova Fairfax Hospital

Laura Nowicki, RN
Nurse Coordinator
Pulmonary Hypertension Program
University of North Carolina at Chapel Hill

Kishan Parikh, MD
Assistant Professor of Medicine
Division of Cardiology
Duke University Medical Center

Sudarshan Rajagopal, MD, PhD
Associate Professor of Medicine
Co-Director, Duke Pulmonary Vascular Disease Center
Division of Cardiology
Duke University Medical Center

Jordan Whitson, MD
Medical Instructor in the Department of Medicine
Division of Pulmonary, Allergy and Critical Care Medicine
Duke University Medical Center

Yen-Rei Andrea Yu, MD
Assistant Professor of Medicine
Division of Pulmonary, Allergy and Critical Care Medicine
Duke University Medical Center

Target Audience

This program is designed to meet the continuing education (CE) needs of pulmonologists, cardiologists, nurses, pharmacists, and other allied healthcare professionals involved in the treatment of pulmonary hypertension.

Learning Objectives

  • Describe classification of Pulmonary Hypertension, according to the World Symposium classifications and including updates from the 6th World Symposium, as well as the treatment options with respect to PAH-specific therapies.
  • Recognize and distinguish similar disease processes that may or may not respond to Pulmonary Arterial Hypertension specific therapy.
  • Understand diagnostics used in the evaluation of pulmonary hypertension, including echocardiography, CT scan, VQ scan, and right heart catheterization hemodynamic profiles.
  • Identify various PH subtypes and understand their diagnosis and clinical course, particularly chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with lung disease.
  • Identify the role of clinical trials in the development of new PAH therapies, with a particular appreciation of the patient perspective as a clinical trial subject.
  • Identify different endpoints in pulmonary arterial hypertension clinical trials, including six-minute walk distance, time to clinical worsening, and quality of life scores.
  • Recognize the importance of access to pulmonary arterial hypertension therapies for patients.
  • Describe the importance of screening for CTEPH and referral for definitive therapy, as well as gain knowledge on new developments in the field of CTEPH.

Joint Accreditation Statement

This activity has been planned and implemented by the Duke University Health System Department of Clinical Education & Professional Development for the advancement of patient care. In support of improving patient care, the Duke University Health System Department of Clinical Education & Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team.

Category 1: Duke University Health System Department of Clinical Education and Professional Development designates this activity for a maximum of 4 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Nurse CE: Duke University Health System Department of Clinical Education and Professional Development designates this activity for up to 4 credit hours for nurses. Nurses should claim only credit commensurate with the extent of their participation in this activity.

Pharmacists: Duke University Health System Department of Clinical Education and Professional Development designates this activity for a maximum of 4 ACPE credit hours. Universal Activity Numbers: JA0000655-0000-20-032-L04-P

Registration Fees*

Registration for the symposium is complimentary, but required. Please click button below to register.

Register Here

Cancellation Policy

All cancellation requests must be submitted in writing to Christy Darnell via email (christy.darnell@duke.edu).

After the Event

To complete all course requirements and claim continuing education credits, please do the following:

  • Complete the course evaluation.
  • Attest to your hours of completion.
  • Download your certificate.